Migdal Insurance & Financial Holdings Ltd. reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 7.5% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 665,557 shares of the biopharmaceutical company’s stock after selling 54,213 shares during the period. Migdal Insurance & Financial Holdings Ltd.’s holdings in Pfizer were worth $22,356,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Arrowstreet Capital Limited Partnership purchased a new position in Pfizer in the second quarter valued at about $1,072,000. Moors & Cabot Inc. increased its holdings in Pfizer by 1.0% in the second quarter. Moors & Cabot Inc. now owns 183,079 shares of the biopharmaceutical company’s stock valued at $6,156,000 after buying an additional 1,765 shares in the last quarter. KLCM Advisors Inc. increased its holdings in Pfizer by 3.6% in the second quarter. KLCM Advisors Inc. now owns 405,626 shares of the biopharmaceutical company’s stock valued at $13,625,000 after buying an additional 14,139 shares in the last quarter. Carret Asset Management LLC increased its holdings in Pfizer by 7.4% in the second quarter. Carret Asset Management LLC now owns 119,500 shares of the biopharmaceutical company’s stock valued at $4,014,000 after buying an additional 8,265 shares in the last quarter. Finally, First Commonwealth Financial Corp PA increased its holdings in Pfizer by 35.2% in the second quarter. First Commonwealth Financial Corp PA now owns 10,404 shares of the biopharmaceutical company’s stock valued at $350,000 after buying an additional 2,706 shares in the last quarter. 69.89% of the stock is owned by hedge funds and other institutional investors.

In related news, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the sale, the insider now owns 117,432 shares in the company, valued at $4,145,349.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the sale, the executive vice president now owns 117,432 shares in the company, valued at approximately $4,186,450.80. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by company insiders.

A number of research analysts have issued reports on PFE shares. Cowen set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Monday, August 14th. BMO Capital Markets set a $37.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, October 10th. ValuEngine raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price for the company in a report on Tuesday, October 3rd. Finally, Sanford C. Bernstein set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, September 19th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $38.77.

Shares of Pfizer Inc. (NYSE:PFE) traded up $0.47 on Tuesday, hitting $36.21. 14,362,900 shares of the stock were exchanged, compared to its average volume of 19,915,859. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer Inc. has a fifty-two week low of $30.90 and a fifty-two week high of $36.78. The stock has a market cap of $213,035.67, a PE ratio of 14.30, a price-to-earnings-growth ratio of 2.52 and a beta of 1.01.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. During the same quarter last year, the business earned $0.61 earnings per share. Pfizer’s revenue was up .9% compared to the same quarter last year. equities analysts expect that Pfizer Inc. will post 2.59 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were given a dividend of $0.32 per share. The ex-dividend date was Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.53%. Pfizer’s dividend payout ratio (DPR) is currently 79.01%.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/12/migdal-insurance-financial-holdings-ltd-has-22-36-million-position-in-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related stocks with our FREE daily email newsletter.